Depression is a prevalent condition with increasing rates.
Traditional antidepressants often yield limited results.
Novel treatments focus on diverse brain systems and neurotransmitter pathways.
These treatments show potential for improved outcomes in depression.
Early antidepressants (1950s): monoamine oxidase inhibitors (MAOIs).
Development of tricyclic antidepressants (TCAs) in the 1960s.
Introduction of selective serotonin reuptake inhibitors (SSRIs) in the 1980s.
Side effects of these medications can be significant, including dry mouth, constipation, insomnia, and sexual dysfunction.
Slow onset of action (weeks) leads to high dropout rates.
Recent theories emphasize stress and neuroplasticity in depression.
Stress linked to increased depression risk and resistance to treatment.
Neuroplasticity refers to the brain's ability to adapt and change.
Reduced neuroplasticity observed in individuals with depression.
Psychedelics show promise in treating depression.
They elevate serotonin and dopamine levels in the brain.
Potential benefits include reduced inflammation and enhanced neuroplasticity.
Ketamine possesses rapid-acting antidepressant effects.
Mechanism of action: blocking NMDA receptors in the brain.
Auvelity targets the glutamate system for fast action.
SAINT represents a novel protocol for TMS therapy.
Uses light and genetic tools to manipulate neuron activity.
Potential for selective targeting of specific cellular pathways in depression.
Potential to generate new neurons and connections in the brain.
Could lead to improvements in mood and function.
The field of depression treatment is undergoing rapid advancements.
Novel treatments have shown potential for improved outcomes.
Ongoing research holds promise for new and effective therapies.